FibroBiologics宣布注册直接发行170万美元

2025-12-15 21:56

FibroBiologics (NASDAQ:FBLG) announced on Monday that it has entered into an agreement for the issuance and sale of an aggregate of 5.23M shares of its common stock at an offering price of $0.33 per share in a registered direct offering priced at-the-market under Nasdaq rules.
Concurrently, the company will issue unregistered warrants to purchase up to an aggregate of 5.23M shares of common stock at an exercise price of $0.33 per share.
The closing of the offering is expected to occur on or about December 16, 2025, subject to the customary closing conditions.
The company expects $1.7M in gross proceeds from the offering, intending to use it for working capital and general corporate purposes.
The shares in the registered direct offering are being offered pursuant to a registration statement filed with the SEC on February 3, 2025, which became effective on February 10, 2025.

More on FibroBiologics